Schizophrenia Pipeline Therapeutics Development, Drug Profiles and Key Players Market Analysis Report Now Available at RnRMarketResearch.com

PUNE, India, June 1, 2017 /PRNewswire/ --

RnRMarketResearch.com adds "Schizophrenia - Pipeline Review, H1 2017" therapeutic market research report of 309 pages with latest updates, data and information to its online business intelligence library.

The report "Schizophrenia - Pipeline Review, H1 2017" provides comprehensive information on the therapeutics under development for Schizophrenia (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Schizophrenia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Complete report on Schizophrenia - Pipeline Review, H1 2017 spread across 309 pages is available at http://www.rnrmarketresearch.com/schizophrenia-pipeline-review-h1-2017-market-report.html .

Schizophrenia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 12, 13, 22, 1, 54, 10 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 9 and 2 molecules, respectively.

Companies discussed in this report include Acadia Pharmaceuticals Inc, Adamed Sp z oo, Aequus Pharmaceuticals Inc, AgeneBio Inc, Alkermes Plc, Angita BV, Astellas Pharma Inc, Athersys Inc, Avanir Pharmaceuticals Inc, Avineuro Pharmaceuticals Inc, BCWorld Pharm Co Ltd, BioCrea GmbH, BioHealthonomics Inc, Boehringer Ingelheim GmbH, Braeburn Pharmaceuticals Inc, Bristol-Myers Squibb Company, Critical Pharmaceuticals Ltd, Curemark LLC, Daewoong Pharmaceutical Co Ltd, Delpor Inc, Denovo Biopharma LLC, Evotec AG, F. Hoffmann-La Roche Ltd, Fabre-Kramer Pharmaceuticals Inc, Galenea Corp, GeNeuro SA, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd, GP Pharm SA, GW Pharmaceuticals Plc, H. Lundbeck A/S, Heptares Therapeutics Ltd, Hisamitsu Pharmaceutical Co Inc, Indivior Plc, Insys Therapeutics Inc, IntelGenx Corp, Intra-Cellular Therapies Inc, Johnson & Johnson, JT Pharmaceuticals Inc, Karuna Pharmaceuticals Inc, KemPharm Inc, Kowa Company Ltd, Laboratorios Farmaceuticos Rovi SA, Lead Discovery Center GmbH, Lohocla Research Corp, Luye Pharma Group Ltd, Mapi Pharma Ltd, Merck & Co Inc, Mitsubishi Tanabe Pharma Corp, Neurocrine Biosciences Inc, NeurOp Inc, Newron Pharmaceuticals SpA, Omeros Corp, Otsuka Holdings Co Ltd, Peptron Inc, Pfizer Inc, Promentis Pharmaceuticals Inc, Ra Pharmaceuticals Inc, Reviva Pharmaceuticals Inc, Richter Gedeon Nyrt, Sage Therapeutics Inc, SK Biopharmaceuticals Co Ltd, Sumitomo Dainippon Pharma Co Ltd, Sunovion Pharmaceuticals Inc, Suven Life Sciences Ltd, Taisho Pharmaceutical Holdings Co Ltd, Tetra Discovery Partners LLC, Teva Pharmaceutical Industries Ltd, Vanda Pharmaceuticals Inc, Vitality Biopharma Inc, VLP Therapeutics LLC, Zogenix Inc, Zysis Ltd

Order a copy of this research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=1019645. (This report is available at up to 25% Discount till June 02nd 2017.)

Related reports on Schizophrenia:

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2017

"Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2017", provides comprehensive information on the therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Explore more reports of Therapeutics Market Research at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics .

About Us: 

RnRMarketResearch.com is your one stop market research and industry analysis reports' library providing business data and intelligence information on thousands of micro markets with global as well as regional coverage. Category focused research, country reports, company profiles, regional and global industry profiles and guides to premium reports offering extensive coverage of other 20+ industries are all available in our library of syndicated market research reports.

Contact:
Ritesh Tiwari
2nd Floor, Metropole,
Bund Garden Road,
Pune - 411001,
India.
Tel: +1-888-391-5441
E-mail: [email protected]

SOURCE RnRMarketResearch